Business Strategies by Process Pipeline

Status of drug candidates (as of July 25, 2019)

Asia: excluding Japan and China

Development code Product name (Generic name)				Stage		
	Category	Indications	Region	Phase 1 2 3	Filed	Origin
Immuno-inflammation						
	ully human anti-NGF nonoclonal antibody	Osteoarthritis	Japan		Phase 2/3	US: Regeneron
MT-1303 S1P receptor functional antagonist		Multiple sclerosis	Europe			In-house
		Crohn's disease	Japan			
MT-7117 De	ermatologicals, etc.	Erythropoietic protoporphyria	Global			In-house
	Fully human anti-interleukin-33 (IL-33) monoclonal antibody	Endometriosis	Global			In-house
(IL-		Seasonal Allergic Rhinitis	-			
Diabetes and kidney						
TA-7284	CLTD: 1117	Type 2 diabetes mellitus	Asia			In-house
Canaglu SG (Canagliflozin)	SGLT2 inhibitor	Diabetic nephropathy	Japan			
		Type 2 diabetes mellitus	Asia			In-house
MP-513 Tenelia DP (Teneligliptin)	DPP-4 inhibitor		China			
(Terteligipuit)			Europe			
	ypoxia inducible factor rolyl hydroxylase inhibitor	Renal anemia	Japan		19.07	US: Akebia
	Selective mineralocorticoid receptor antagonist	Diabetic nephropathy	Europe			In-house
W11-3995			Japan			
rec		Non-alcoholic steatohepatitis: NASH	Japan			
Central nervous system	<u>'</u>					
MCI-186	Free radical scavenger	Amyotrophic lateral sclerosis: ALS	China		19.04	1.1.
Radicut/Radicava Free (Edaravone)			Asia			In-house
	opamine D3/D2 receptor artial agonist	Schizophrenia	Asia			Hungary: Gedeon Richter
	esicular monoamine ansporter type 2 inhibitor	Tardive dyskinesia	Japan		Phase 2/3	US: Neurocrine Biosciences
	TRPM8 antagonist	Painful diabetic peripheral neuropathy	Europe			In-house
MT-8554 TR		Vasomotor symptoms associated with menopause	Global			
	ontinuous SC pump/ atch pump	Parkinson's disease	Global			In-house
ND0701 (Apomorphine)	ontinuous SC pump	Parkinson's disease	_			In-house
MT-1186 (Edaravone)	ree radical scavenger	Amyotrophic lateral sclerosis: ALS/Oral suspension	_			In-house
MT-6345 Ne	ervous system	-	_			Japan: Co-developed with Ube Industries
MT-3921 An	nti-RGMa antibody	Spinal cord injury	_			Japan: Co-developed with Osaka University

Asia: excluding Japan and China

Development code Product name	Category	Indications	Region	Stage	Origin		
				Phase Filed			
(Generic name)				1 2 3			
Vaccines							
MT-2355	Combined vaccine	Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants	Japan		Japan: Co-developed with The Research Foundation for Microbial Diseases of Osaka University		
MT-2271	Plant-based VLP vaccine	Prophylaxis of seasonal influenza/adults	US, Europe		Canada: Medicago product		
		Prophylaxis of seasonal influenza/elderly	US, Europe				
MT-8972	Plant-based VLP vaccine	Prophylaxis of H5N1 influenza	Canada		Canada: Medicago product		
MT-7529	Plant-based VLP vaccine	Prophylaxis of H7N9 influenza	-		Canada: Medicago product		
MT-5625	Plant-based VLP vaccine	Prophylaxis of rotavirus gastroenteritis	-	_	Canada: Medicago product		
Others							
TAU-284 Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent	Allergic rhinitis, Urticaria	Asia		Japan: Licensed from Ube Industries		
MT-4129	Cardiovascular system, etc.	_	_		In-house		

Major out-licensed products

Development code				Stage		
Product name (Generic name)	Category	Indications	Region	Phase Filed	licensee	
Diabetes and kidney						
TA-7284 INVOKANA (Canagliflozin)	SGLT2 inhibitor	Diabetic nephropathy	US	19.03	US: Janssen Pharmaceuticals	
Central nervous system						
MT-210	5-HT2A/Sigma 2 receptor antagonist	Schizophrenia	US, Europe		US: Minerva Neurosciences	
Others						
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist	Hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism	Japan	19.04	Japan: Licensed to Kyowa Kirin	